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Objective:	Chronic,	low-	level	inflammation	is	associated	with	symptomatic	bipolar	dis-
order	(BD)	and	with	chronic	insomnia.	Disrupted	sleep	is	a	feature	of	episodes	of	both	
mania	and	depression.	We	examined	the	effect	of	neopterin,	a	marker	of	cellular	im-
mune	activation,	and	kynurenine	(KYN),	an	inflammatory	byproduct	of	the	serotonin	
pathway,	on	the	association	between	total	sleep	time	and	depression	severity	in	BD.
Method:	Twenty-	one	symptomatic	BD	participants	and	28	healthy	controls	(HC)	were	
recruited	and	followed	during	usual	clinical	care.	At	baseline	and	after	symptomatic	
recovery,	total	sleep	time	was	objectively	measured	with	actigraphy	for	1	week	and	
blood	 plasma	was	 collected	 to	measure	 the	 serotonin	 precursor	 tryptophan	 (TRP),	
KYN,	 the	KYN/TRP	ratio,	and	neopterin	 levels.	Statistical	analyses	were	conducted	
using	 chi-	square,	 independent	 t	 tests	 and	 hierarchical	 linear	 multiple	 regression	
models.
Results:	Total	sleep	time	was	correlated	positively	with	depressive	severity	and	nega-
tively	with	manic	severity.	TRP	was	significantly	reduced	in	BD	participants	compared	
to	HC.	KYN,	TRP,	and	the	KYN/TRP	ratio	were	associated	with	depressive	severity	
when	total	sleep	time	and	body	mass	 index	 (BMI)	were	 included	 in	 the	model.	The	
KYN/TRP	ratio	trended	towards	a	negative	association	with	mania	symptoms,	control-
ling	for	BMI	and	total	sleep	time,	in	acutely	symptomatic	BD	participants.	Neopterin	
was	not	associated	with	sleep	or	mood	severity.	After	usual	clinical	care,	BD	partici-
pants	showed	significantly	decreased	clinical	symptoms	but	no	significant	differences	
in	sleep	phenotype	or	biomarkers.
Conclusion:	 Inflammation,	sleep,	and	mood	are	closely	 intertwined.	Future	research	
into	 the	 effect	 of	 inflammation	 on	 sleep	 in	 BD	 may	 lead	 to	 clinical	 markers	 of	
outcome.
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1  | INTRODUCTION
Bipolar	disorder	(BD)	is	a	severe	psychiatric	disorder,	with	a	complex	
and	sometimes	heterogeneous	range	of	symptoms.1	BD	is	one	of	the	
leading	causes	of	disability,	demonstrating,	on	average,	a	less	favorable	
prognosis	than	major	depressive	disorder	(MDD).2	As	a	clinically	het-
erogeneous	syndromic	disorder,	the	biological	changes	in	BD	have	been	
reported	in	depressive	and	manic	episodes,	and	any	unifying	biologi-
cal	underpinnings	of	this	disorder	have	remained	elusive.3-5	Research	
shows	 that	 BD	 presents	with	 numerous	 immune-	inflammatory	 and	
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sleep	 abnormalities.6-8	Activation	 of	 the	 kynurenine	 (KYN)	 pathway	
has	 been	 supported	 in	 a	 number	 of	 psychiatric	 disorders,	 including	
BD9,10.While	 many	 studies	 have	 independently	 explored	 sleep,11-13 
inflammation,7,14	and	the	KYN9,15	pathway	in	BD,	there	is	increasing	
evidence	 that	 inflammation	 is	 an	 important	 factor	 in	 mood,	 stress,	
and	sleep	disturbance16,17	and	needs	to	be	examined	simultaneously	
for	a	better	understanding	of	 the	underlying	biological	mechanisms.	
Additionally,	there	is	a	dearth	of	research	exploring	inflammation,	me-
tabolites	of	the	KYN	pathway,	or	sleep	in	acutely	ill	BD	patients.4
Mood	spectrum	disorders	(BD,	recurrent	depressive	disorder,	and	
seasonal	affective	disorder)	are	accompanied	by	sleep	dysregulations	
that	are	particularly	common	among	bipolar	participants.8,12,13,18 Sleep 
dysregulations	 in	mood	disorders	commonly	occur	 in	acute	manic	or	
depressive	states	but	are	also	prevalent	during	remission.8,19-21	A	meta-	
analysis	focusing	on	sleep	in	remitted	BD	participants	highlights	distur-
bances	in	several	sleep	parameters:	longer	sleep	latency,	longer	sleep	
duration,	and	poorer	sleep	efficiency.21	Sleep	is	a	remarkably	sensitive,	
but	not	specific,	indicator	of	distress,	and	dysregulated	sleep	can	occur	
for	a	variety	of	reasons.	Inflammation	has	been	shown	to	be	associated	
with	sleep	disturbance	and	objective	short	sleep	in	primary	insomnia	
and	 obstructive	 sleep	 apnea,	 and	 may	 mediate	 the	 association	 be-
tween	sleep	apnea	and	adeposity.22-24	By	examining	the	association	of	
sleep	dysregulation	with	inflammatory	biomarkers	in	BD,	we	may	gain	
an	understanding	of	the	sleep,	mood,	and	inflammation	connection.
The	essential	amino	acid	tryptophan	(TRP)	is	a	substrate	for	two	
important	biosynthetic	pathways:	the	serotonin	(5-	hydroxytryptamine	
[5-	HT])	 pathway	 and	 the	 KYN	 pathway	 (Figure	1).	 During	 stress,	
proinflammatory	 cytokines	 activate	 the	 KYN	 pathway	 and	 deprive	
the	 serotonin	 pathway	 of	 TRP,	 thereby	 reducing	 serotonin	 syn-
thesis.	The	 dynamics	 of	 this	 process	 are	 characterized	 best	 by	 the	
kynurenine-	to-	TRP	(KYN/TRP)	ratio.	One	of	the	inflammatory	drivers	
of	this	diversion	of	serotonin	to	KYN	is	neopterin,	a	catabolic	prod-
uct	 of	 guanosine	 triphosphate	 that	 is	 a	 marker	 of	 cellular	 immune	
system	 activation	 produced	 by	 macrophages	 upon	 stimulation	 by	
interferon-	gamma.25-28	Increased	peripheral	KYN	results	in	increased	
central	KYN.	KYN	is	further	broken	down	into	quinolinic	acid,	which	
is	 a	 potent	 agonist	 at	 the	N-	methyl-	D-	aspartate	 (NMDA)	 receptor,	
causing	excitotoxic	effects	 through	 receptor	overactivation29,30 and 
inhibiting	glutamate	uptake,	causing	elevated	extracellular	glutamate	
concentrations.31
In	 the	 current	 study,	 we	 investigated	 the	 relationship	 between	
markers	of	the	KYN	pathway,	neopterin,	sleep,	and	clinical	symptoms	
in	 acutely	 ill	 BD	 participants.	We	were	 also	 interested	 in	 exploring	
biomarkers	and	sleep	patterns	after	symptom	remission,	to	determine	
whether	these	biomarkers	were	potentially	state	vs	trait	characteris-
tics	independent	of	mood	state.	We	hypothesized	that:
1. Patients	with	 acute	BD	would	have	 significantly	 lower	 total	TRP	
and	 a	 higher	 KYN/TRP	 ratio	 and	 neopterin	 levels	 than	 healthy	
controls	 (HC).
2. The	KYN/TRP	ratio	and	neopterin	would	be	associated	with	sever-
ity	of	depressive	and	manic	symptoms	in	acutely	symptomatic	par-
ticipants	with	BD.
3. Sleep	duration	and	biomarkers	including	kynurenine	pathway	me-
tabolites	(TRP,	KYN/TRP)	and	the	proinflammatory	cytokine	neop-
terin	 would	 be	 associated	 with	 depressive	 and	 manic	 symptom	
severity.
Finally,	we	were	interested	in	whether	these	markers	changed	with	
symptom	remission	in	asymptomatic	patients,	and	explored	differences	
in	clinical	symptoms,	sleep,	and	biomarkers	between	baseline	and	follow	
up.
F I G U R E  1 The	kynurenine	pathway.	
INF-	γ,	interferon-	gamma;	TNF-	α,	
tumor	necrosis	factor-	alpha;	TPH	IDO,	
indolamine-2,3-dioxygenase;	KAT,	
kynurenine	aminotransferase;	KMO,	
kynurenine	3-monooxygenase;	KYNU,	
kynureninase;	TDO,	tryptophan-2,3-
dioxygenase;	TPH,	tryptophan	hydroxylase
Tryptophan Serotonin
Kynureninc acid3-hydroxykynurenine      
Quinolinic acid
IDO
Kynurenine
TDO
KYNU
KATKMO
TPHs
TNF-α, INF-γ
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2  | PARTICIPANTS AND METHODS
2.1 | Participants
Thirty	BD	participants	with	current	mood	symptoms	participated	 in	
the	study,	and	21	completed	all	measures	for	this	analysis.	Participants	
were	recruited	when	presenting	for	inpatient	or	partial	hospital	care	
at	 the	Pennsylvania	Psychiatric	 Institute,	under	 Institutional	Review	
Board	 Protocol	 No.	 39164EP	 and	 NIH	 Office	 of	 Human	 Subject	
Research	Exemption	#11509	(7/16/2012).	Participants	were	screened	
and	consented	for	the	study,	and	assessments	including	sleep	and	bio-
markers	were	administered	while	they	were	receiving	inpatient	or	par-
tial	hospital	care.	Inclusion	criteria	for	BD	participants	included	adults	
with	a	primary	diagnosis	of	BD	I	or	II.	Exclusion	criteria	included	use	of	
nonsteroidal	anti-	inflammatory	drugs	(NSAIDs)	on	a	daily	basis,	active	
substance	intoxication	or	withdrawal,	major	endocrinological	or	rheu-
matological	illness,	or	pregnancy.	Twenty-	eight	HC	participants	were	
recruited	via	advertisement,	based	on	the	inclusion	criteria	that	they	
had	no	personal	or	family	history	of	mental	illness,	rheumatological	or	
endocrinological	illness,	pregnancy,	or	daily	NSAID	use.	HCs	provided	
actigraphy	data	 in	 their	home	environment,	while	clinical	and	blood	
measures	were	collected	at	the	research	site.
2.2 | Measures
Structured	 clinical	 interview	 based	 on	 the	 Mini	 Neuropsychiatric	
Interview32	 were	 conducted	 and	 current	 mood	 state	 was	 assessed	
using	 the	 Hamilton	 Depression	 Rating	 Scale-	21	 plus	 atypical	 items	
(HDRS-	21+AT),33	 and	 the	 Clinician-	Administered	 Rating	 Scale	 for	
Mania	 (CARS-	M).34	A	combination	of	clinically	significant	manic	and	
depressed	 symptoms	 defined	 a	 mixed-	manic	 phenotype.	 HDRS-	
21+AT	scores	between	0	and	6	 indicated	no	depression;	scores	be-
tween	7	and	17	indicated	mild	depression;	scores	between	18	and	24	
indicated	moderate	depression;	and	scores	over	24	indicated	severe	
depression.	 CARS-	M	 scores	 below	 7	 were	 considered	 non-	manic.	
Scores	between	7	and	12	were	mild,	and	above	12	were	severe	manic	
phenotypes.	The	body	mass	index	(BMI)	for	each	participant	was	cal-
culated	by	measuring	height	and	weight.	Participants	received	usual	
clinical	care	and	were	discharged	from	the	program.	After	discharge	
from	 the	hospital	or	partial	 hospital	program,	participants	were	 fol-
lowed	 each	 week	 by	 telephone	 and	 assessed	 for	 clinical	 improve-
ment.	A	return	visit	was	scheduled	to	collect	a	second	blood	sample	
when	the	subject	was	asymptomatic,	or	after	3	months	had	elapsed.	
Additional	 measures	 were	 collected	 but	 not	 used	 for	 this	 analysis.	
Saunders	et	al35	provided	a	more	detailed	report	on	the	methods	and	
results	of	analysis	of	fatty	acid	concentrations.
2.3 | Objective measure of total sleep time
During	the	period	of	initial	evaluation,	participants	wore	an	actigraph	
(Sleepwatch-	O,	 Ambulatory	 Monitoring,	 Inc.,	 Ardsley,	 NY,	 USA),	 a	
watch-	like	 device	 that	 measures	 acceleration,	 on	 the	 nondominant	
hand	for	7	days.	They	also	maintained	a	sleep	 log,	which,	combined	
with	the	actigraphy	recording,	provides	an	accurate	assessment	of	ob-
jective	sleep	measures.	ActiLife	V.6.4.5	software	(ActiGraph	Software	
Department,	Pensacola,	FL,	USA)	was	used	to	compute	the	actigraphy	
sleep	 variables,	 including	 total	 sleep	 time,	 bedtime	 variability,	 sleep	
latency,	 sleep	 duration,	 and	 sleep	 efficiency.	 BD	 participants	 com-
pleted	the	actigraph	during	hospitalization,	and	HCs	completed	 it	at	
home.	Owing	to	the	small	sample	size,	we	limited	the	analysis	of	sleep	
variables	to	the	investigation	of	total	sleep	time	only,	which	allowed	
us	to	conserve	statistical	power.	However,	an	additional	exploratory	
analysis	of	mean	 lag	 (variability	 in	bedtime	from	night	 to	night)	was	
also	made.
2.4 | Sample collection and biochemical analysis
Participants	 fasted	for	at	 least	6	hours,	and	blood	was	drawn	 in	va-
cutainers	 containing	 ethylenediaminetetraacetic	 acid	 (EDTA)	 in	
the	morning.	 BD	participants	 had	 blood	 drawn	between	07:15	 and	
10:30	 (average	 time	 08:24)	 and	 HC	 participants	 had	 blood	 drawn	
between	08:00	and	14:00	(average	time	09:19).	After	centrifugation	
for	10	minutes	at	654.03	g,	 the	plasma	supernatant	was	transferred	
to	plastic	tubes	and	maintained	at	−80°C	until	processed.	Total	TRP	
(micromoles	per	liter)	and	KYN	(micromoles	per	liter)	were	measured	
by	reverse-	phase	high-	performance	liquid	chromatography,	as	previ-
ously	described36,37,	using	3-	nitro-	L-	tyrosine	as	an	internal	standard.	
The	KYN/TRP	ratio	was	calculated	(expressed	as	micromoles	of	KYN	
per	millimoles	 of	 TRP).	 Neopterin	was	measured	 by	 enzyme-	linked	
immunosorbent	 assay	 (BRAHMS,	 Hennigsdorf,	 Germany)	 according	
to	the	manufacturer’s	instructions,	with	a	detection	limit	of	2	nmol/L.
2.5 | Data and statistical analysis
SPSS	 version	 22	 (IBM	 SPSS	 Statistics,	 IBM	 Corporation,	 Armonk,	
NY,	USA)	was	used	for	all	statistical	calculations.	Values	of	continu-
ous	variables	were	compared	between	the	BD	and	HC	groups	using	
independent-	samples	t	tests,	and	categorical	variables	were	compared	
using	the	Pearson	chi-	square	test.	Paired	t	tests	were	used	for	baseline	
and	 follow-	up	 measurements.	 In	 an	 exploratory	 analysis,	 Pearson’s	
r	was	used	 for	separate	bivariate	correlations	on	demographics	and	
clinical	 symptoms,	 sleep,	 and	 inflammation	 variables	 in	 the	BD	 and	
HC	samples.	Baseline	depression	was	predicted	using	 linear	 regres-
sion	models	 based	 on	 a	 priori	 variables,	 controlling	 for	BMI	 due	 to	
the	known	association	between	inflammation	and	obesity.38	Model	1	
included	total	sleep	time	and	KYN/TRY,	model	2	included	total	sleep	
time	and	KYN,	model	3	included	total	sleep	time	and	TRP,	and	model	
4	had	total	sleep	time	and	neopterin	as	predictor	variables.	The	same	
models	were	implemented	to	predict	baseline	manic	symptoms	con-
trolling	for	BMI.	Paired	t	tests	were	conducted	to	compare	symptoms,	
total	sleep	time,	and	inflammatory	variables	from	baseline	to	follow-
	up.	However,	 follow-up	 data	were	 available	 for	 considerably	 fewer	
participants.	This	was	the	result	of	an	inability	to	maintain	regular	con-
tact	with	some	participants	owing	to	a	number	of	issues	(e.g.,	unstable	
housing	conditions).	The	maximum	number	of	days	to	follow-	up	was	
187;	the	median	was	22	days	and	the	average	was	52	days.	However,	
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an	analysis	of	dropouts	vs	those	who	continued	to	be	a	part	of	 the	
study	did	not	show	any	significant	differences	based	on	baseline	clini-
cal	symptoms	and	demographics,	including	age	and	gender	(P	values	
>.16).	Dependent	variables	were	compared	between	BD	smokers	and	
nonsmokers	using	independent	t	tests.
3  | RESULTS
3.1 | Demographic and clinical description of the 
sample
A	cohort	of	30	participants	with	BD	was	recruited	while	in	a	sympto-
matic	mood	episode.	Six	participants	did	not	have	sleep	assessment	
data,	and	three	did	not	have	biomarker	data;	 therefore,	21	BD	par-
ticipants	were	included	in	the	final	analysis.	A	parallel	HC	group	of	31	
participants	was	recruited	for	the	study,	of	which	three	participants	
did	not	have	sleep	data	 (n	=	28).	Participants	with	BD	did	not	differ	
from	 the	HC	group	 in	 age,	 gender,	 or	 race	 (Table	1).	A	 significantly	
higher	proportion	of	participants	with	BD	were	unemployed,	not	mar-
ried,	and	smokers	than	in	the	HC	group	(Table	1).	Independent	t	tests	
were	run	between	the	smokers	and	nonsmokers	within	the	BD	group,	
to	detect	any	differences	based	on	age,	BMI,	HDRS,	CARS-	M,	TRP,	
KYN,	KYN/TRP,	and	sleep	variables.	No	differences	were	detected,	
with	all	P	values	above	.10.
Clinically,	BD	individuals	had	a	significantly	higher	BMI,	and	when	
evaluated	 for	 the	 study	 exhibited,	 on	 average,	 severe	 depressive	
symptoms	and	moderate	manic	symptoms	(Table	1).
3.2 | Sleep and inflammation variables
The	HC	 group	 slept	 an	 average	 of	 6.9	hours	 a	 night,	with	 a	 stand-
ard	deviation	of	 about	1	hour;	 and	 the	mean	 lag	 (variability	 in	bed-
time	from	night	to	night)	was	4	minutes,	with	a	standard	deviation	of	
1	hour.	The	BD	group	slept	an	average	of	6.5	hours,	with	a	standard	
deviation	of	almost	2	hours,	and	the	mean	lag	was	23	minutes,	with	
a	standard	deviation	of	60	minutes.	Total	sleep	time	was	correlated	
positively	with	depressive	symptom	severity	and	negatively	with	the	
severity	of	manic	symptoms	(Table	2).
3.2.1 | Group comparisons of TRP, KYN/TRP, and  
neopterin
As	hypothesized,	the	BD	group	had	significantly	lower	levels	of	TRP	
than	 the	HC	 group	 (P	<	.03)	 (Table	1).	 The	BD	 group	 did	 not	 differ	
significantly	from	the	HC	group	in	mean	levels	of	KYN,	KYN/TRP,	and	
neopterin	(Table	1).
3.2.2 | TRP, KYN/TRP, and neopterin, and severity of 
depressive and manic symptoms
Based	on	Pearson’s	 correlation	 test,	KYN,	KYN/TRP,	 and	neopterin	
did	not	correlate	significantly	with	depressive	and	manic	symptoms,	
as	measured	 by	 the	HDRS	 and	 CARS-	M	 clinical	measures	 or	 sleep	
measures,	 including	 total	 sleep	 time	 and	 bedtime	 variability.	 None	
of	the	kynurenine	pathway	markers	were	associated	with	total	sleep	
time	in	either	the	BD	or	HC	group.	Neopterin	levels	correlated	posi-
tively	with	KYN/TRP	 (r	=	.53,	P	<	.01)	but	were	not	 correlated	with	
clinical	severity,	TRP,	or	KYN	(Table	3).
3.2.3 | Association of biomarkers and sleep with 
depressive and manic severity
The	 association	of	 depressive	 severity	was	 tested	with	 four	 hierar-
chical	regression	models,	using	depressive	severity	as	the	dependent	
variable	and	total	sleep	time,	KYN,	TRP,	and	KYN/TRP	as	the	predic-
tor	 variables	 controlling	 for	 BMI	 (Table	4).	Depressive	 severity	was	
TABLE  1 Demographics,	clinical	symptoms,	and	differences	in	
sleep	and	biomarkers	between	healthy	controls	and	bipolar	disorder	
individuals
Healthy control Bipolar disorder
PN (%) N (%)
Total	sample	size 28 21
Gender	(F) 16	(57%) 10	(48%) .57
Race
Asian 3	(11%) 0 .19
Black 1	(4%) 0
White 24	(86%) 21	(100%)
Marital	status .02
Married 14	(50%) 4	(18.2%)
Not married 14	(50%) 17	(81.8%)
Employment <.001
Unemployed 2	(7%) 11	(55%)
Disabled 0 4	(20%)
Employed 16	(57%) 4	(20%)
Student 10	(36%) 1	(5%)
Smoking	status 1	(4%/) 11	(52%) <.001
Mean (SD) Mean (SD)
Age	(y) 31.57	(10.33) 36.10	(11.33) .16
Body	mass	
index(kg/m2)
25.01	(4.91) 30.32	(5.49) .001
Mania	(CARS-	M) 0 16.52	(13.87) <.001
Depression	(H-	21) 0.32	(.61) 33.62	(15.37) <.001
Total	sleep	time	
(min)
414.68	(70.98) 392.56	(117.23) .45
Bedtime variability 
(min)
−3.67	(58.31) −22.62	(61.17) .26
KYN	(μmol/L) 1.98	(.55) 1.79	(.50) .22
TRP	(μmol/L) 68.74	(11.62) 60.25	(14.30) .03
KYN/TRP 28.93	(7.26) 29.88	(6.21) .63
Neopterin	(nmol/L) 5.45	(1.39) 5.80	(1.66) .46
KYN,	kynurenine;	Kyn/Trp,	kynurenine/tryptophan	ratio;	SD,	standard	
deviation;	TRP,	tryptophan.
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significantly	associated	with	KYN	(model	3)	and	TRP	(model	4),	when	
total	sleep	time	and	BMI	were	accounted	for.	Models	3	and	4	(Table	4)	
accounted	for	71%	and	60%	of	the	variance,	respectively.	Model	1,	
consisting	of	KYN/TRP	and	total	sleep	time,	trended	toward	signifi-
cance,	 accounting	 for	60%	of	 the	variance	 (Table	4).	Although	 total	
sleep	time	was	significantly	associated	with	manic	severity	in	all	four	
models,	 only	 the	KYN/TRP	biomarker	 trended	 towards	 significance	
(Table	5).	This	model	explained	35%	of	the	variance	(Table	5).
3.3 | Follow- up data
Exploratory	analysis	of	the	follow-	up	data	showed	that	although	the	
BD	participants	reported	significantly	decreased	clinical	symptoms	of	
depression	and	mania,35	no	significant	differences	were	detected	 in	
total	sleep	time,	TRP,	KYN/TRP.	Total	sleep	time	appears	to	have	in-
creased	at	follow-	up	but	was	not	significantly	different	from	baseline	
scores.	This	may	have	been	the	result	of	the	high	variability	 in	total	
sleep	time	score	for	BD	participants	(Table	6).
4  | DISCUSSION
The	current	study	examined	the	relationship	between	objective	mark-
ers	of	sleep	and	biomarkers	of	TRP	metabolism	and	inflammation	in	a	
group	of	acutely	symptomatic	BD	individuals.	We	found	significantly	
lower	levels	of	TRP	in	BD	patients	compared	to	HC.	We	also	found	
that	biomarkers,	in	conjunction	with	total	sleep	time,	were	associated	
positively	with	depressive	severity	and	negatively	with	manic	severity	
in	BD	patients.
Our	first	question	addressed	whether	there	were	group	differences	
between	BD	and	HC	in	total	sleep	time,	TRP,	and	KYN/TRP.	Our	find-
ing	of	 lower	TRP	 levels	 in	acutely	symptomatic	BD	participants	was	
concordant	with	 several	 recent	 reports	 examining	TRP	 levels	 in	 BD	
and	schizophrenia10,39,40	 and	 the	 theory	 that	decreased	plasma	TRP	
levels	 in	BD	participants	may	potentially	 lead	 to	dysfunctional	brain	
serotonin	synthesis	and	release.	TRP	depletion	studies41,42 provide a 
useful	tool	to	examine	the	role	and	association	of	serotonin	in	different	
psychiatric	disorders.	Most	of	the	TRP	depletion	studies	have	focused	
on	unipolar	depression	owing	to	decreased	serotonin	as	an	underlying	
cause.	For	example,	TRP	depletion	has	been	associated	either	with	no	
effect43	or	with	a	slight	but	 insignificant	relapse	of	manic	symptoms	
in	 fully	 recovered	BD	patients.	No	TRP	depletion	studies	have	been	
carried	out	in	acutely	manic	BD	patients.39	The	present	study	provides	
evidence	for	decreased	TRP	levels	in	a	naturalistic	occurrence	of	acute	
mood	episodes.	While	experimental	studies	support	 the	notion	 that	
decreased	levels	may	be	a	precursor	to	a	depressed	mood	state,	in	our	
study	 it	was	unclear	whether	 the	decreased	TRP	 levels	preceded	or	
resulted	from	an	acute	mood	state.
TABLE  2 Bivariate	correlations	among	clinical	symptoms	of	depression,	mania,	inflammation,	and	sleep	variables	in	bipolar	participants	only	
(n	=	21)
HDRS21 CARS-	M BMI Total	sleep	time Mean	lag TRP KYN Kyn/Trp Neopterin
HDRS21 −0.62** 0.11 0.72** −0.32 0.36 0.44 0.14 −0.11
CARS-	M −0.05 −0.52* 0.32 −0.04 −0.25 −0.25 0.36
BMI −0.03 0.21 −0.46* −0.04 0.38 0.24
Total	sleep	time −0.25 0.21 0.03 −0.26 −0.34
Mean	lag −0.05 0.21 0.33 0.25
TRP 0.67** −0.22 −0.19
KYN 0.56* 0.24
Kyn/Trp 0.53*
BMI,	body	mass	index;	CARS-	M,	Clinician-	Administered	Rating	Scale	for	Mania;	HDRS21,	Hamilton	Depression	Rating	Scale-	21;	KYN,	kynurenine;	Kyn/
TrP,	kynurenine/tryptophan	ratio;	TrP,	tryptophan.
*P < .05
**P < .01
TABLE  3 Bivariate	correlations	among	inflammation	and	sleep	variables	in	healthy	control	participants	only	(n	=	28)
BMI Total sleep time Mean lag TRP KYN Kyn/Trp Neopterin
BMI −0.25 0.04 −0.12 −0.08 0.01 −0.010
Total	sleep	time −0.12 −0.07 −0.19 −0.14 0.01
Mean	lag −0.23 0.12 0.31 0.32
TRP 0.479** −0.12 0.18
KYN 0.81** 0.40*
Kyn/Trp 0.60**
BMI,	body	mass	index;	KYN,	kynurenine;	Kyn/TrP,	kynurenine/tryptophan	ratio;	TrP,	tryptophan.
*P < .05
**P < .01
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Secondly,	we	asked	if	TRP,	KYN/TRP,	and	neopterin	were	associ-
ated	with	severity	of	depressive	and	manic	symptoms.	We	did	not	find	
levels	of	neopterin,	an	inflammatory	marker,	to	be	significantly	differ-
ent	from	those	in	HC,	and	they	were	not	associated	with	depression	or	
mania	severity.	However,	neopterin	levels	were	found	to	be	associated	
positively	with	the	KYN/TRP	ratio,	which	replicated	earlier	studies	in-
vestigating	depression	and	chronic	 inflammation.	44,45	Further	mech-
anistic	studies	examining	the	role	of	neopterin	in	mood	disorders	are	
warranted.	 For	 example,	 one	 study25	 found	 that	 significantly	 higher	
levels	 of	 neopterin	 predicted	 poststroke	 depression	 in	 patients	who	
had	previously	experienced	a	major	depressive	episode.	Another	cross-	
sectional	study	found	a	positive	association	between	MDD	with	a	his-
tory	of	suicide	attempt	and	KYN	but	no	association	with	neopterin.44 
However,	similar	to	our	findings,	Sublette	et	al44	found	a	positive	cor-
relation	between	the	cytokine	activation	marker	neopterin	and	KYN/
TRP,	suggesting	that	KYN	production	may	be	influenced	by	inflamma-
tory	processes.	The	present	study	supports	previous	studies	finding	an	
association	between	neopterin	and	the	KYN/TRP	ratio	but	does	not	
support	a	direct	association	between	neopterin	and	mood	disorders.
We	hypothesized	a	significant	association	between	sleep	duration	
and	biomarkers	(TRP,	KYN/TRP,	neopterin),	and	depressive	and	manic	
symptom	severity.	TRP	degradation	follows	one	of	two	main	metabolic	
pathways,	which	ultimately	lead	to	the	production	of	either	serotonin	
and	melatonin,	or	kynurenine	and	its	metabolites	(Figure	1).	Enhanced	
activation	of	the	kynurenine	pathway	due	to	stress	or	an	acute	mood	
state	would	theoretically	hinder	melatonin	production,	thereby	poten-
tially	affecting	the	sleep	patterns	of	patients.6,46,47	Thus,	activation	of	
the	kynurenine	pathway	potentially	 suggests	 the	association	of	 sleep	
and	the	kynurenine	metabolites	with	mood	states.	While	we	did	not	find	
a	 correlation	between	 these	biomarkers	 and	 severity	of	mood	 symp-
toms,	we	found	an	association	with	the	severity	of	clinical	mood	symp-
toms	when	 considering	KYN/TRP	 in	 conjunction	with	objective	 total	
sleep	time.	Neopterin	and	TRP	degradation,	as	measured	by	the	KYN/
TRP,	is	highly	associated	with	immune	activation,	which	in	turn	leads	to	
the	production	of	KYN	instead	of	serotonin	from	TRP;48	however,	in	our	
data	neopterin,	although	correlated	with	KYN/TRP,	was	not	associated	
with	mood	severity,	with	or	without	accounting	for	sleep.	The	associa-
tion	of	KYN,	TRP,	and	total	sleep	time	with	severity	of	depression	and	
manic	symptoms	implies	that	these	pathways	are	related	but	further	re-
search	is	necessary	to	delineate	exactly	how	they	influence	each	other.
Finally,	 we	 asked	whether	 total	 sleep	 time,	 TRP,	 and	 KYN/TRP	
changed	 with	 symptom	 remission	 in	 asymptomatic	 BD	 patients.	
Despite	 subjectively	 reported	 decreased	 clinical	 symptoms,	 no	 dif-
ferences	were	 detected	 in	 the	 biomarkers	 or	 total	 sleep	 time.	 One	
explanation	could	be	the	short	follow-	up	time	–	perhaps	these	mark-
ers	change	on	a	slower	time	scale,	or	they	may	leave	a	long-	term	re-
sidual	mark	of	the	episode,	indicating	a	change	in	physiology	despite	
remission.49-51
However,	the	results	should	be	treated	with	caution	owing	to	the	
small	sample	size	of	the	study.	Additionally,	the	patients	were	all	re-
ceiving	medication	for	an	acute	mood	episode,	which	makes	it	difficult	
to	parse	the	effects	of	medication.	Further,	in	order	to	maximize	sta-
tistical	power,	 the	study	 investigated	only	one	sleep	variable	–	total	
TABLE  4 Association	between	depressive	symptom	severity	and	
total	sleep	time	and	KYN/TRP	ratio	in	bipolar	disorder	(controlling	
for	BMI)	(n	=	21)
Variable β t R Adj.R2
Model	1 0.81 0.60
BMI 0.05 0.34
Total	sleep	time 0.85 5.42**
KYN/TRP 0.32 2.0^
Model	2 0.54 0.24
BMI 0.50 3.85**
Total	sleep	time 0.27 2.15*
Neopterin 0.17 0.92
Model	3 0.85 0.71
BMI 0.21 1.53
Total	sleep	time 0.78 5.88**
KYN 0.39 2.93**
Model	4 0.81 0.60
BMI 0.30 1.83
Total	sleep	time	 0.66 4.53**
TRP 0.35 2.10*
BMI,	body	mass	index;	Kyn,	kynurenine;	Kyn/Trp,	kynurenine/tryptophan	
ratio;	TRP,	tryptophan.
*P < .05
**P < .01
^	=	0.06
TABLE  5 Association	between	manic	symptom	severity	and	total	
sleep	time	and	KYN/TRP	in	the	bipolar	disorder	group	(controlling	
for	BMI)	(n	=	21)
Variable β t R Adj.R2
Model	1	 0.66 0.35
BMI 0.04 0.19
Total	sleep	time −0.69 −3.59*
KYN/TRP −0.39 −2.00**
Model	2 0.40 0.10
BMI 0.17 1.21
Total	sleep	time	 −0.29 −2.12*
Neopterin 0.12 0.90
Model	3	 0.60 0.25
BMI −0.21 −0.57
Total	sleep	time	 −0.57 −2.97*
KYN −0.21 −1.07
Model	4 0.57 0.21
BMI −0.06 −0.28
Total	sleep	time −0.56 −2.76*
TRP 0.05 0.20
BMI,	body	mass	index;	Kyn,	kynurenine;	Kyn/TrP,	kynurenine/tryptophan	
ratio;	Trp,	tryptophan.
*P <. 05
**P = .06
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sleep	time.	However,	sleep	is	a	complex	phenomenon	and	consists	of	
multiple	aspects	which	are	easily	measured	using	actigraphic	devices.	
Based	on	 the	 results	of	 the	present	 study,	 different	 sleep	variables,	
along	with	inflammatory	markers,	warrant	further	investigation	with	a	
larger	sample	size.	Another	important	methodological	factor	was	the	
use	of	a	structured	hospitalized	setting	compared	to	a	home	environ-
ment.	It	may	be	argued	that	a	hospitalized	setting	led	to	patients	feel-
ing	more	stressed	than	the	HC;	however,	we	argue	that	the	patients	
were	already	in	acute	distress	and	unable	to	cope	with	their	existing	
resources,	leading	to	inpatient	hospitalization.	The	structured	setting	
of	the	hospital	often	relieves	stress	through	 learning	basic	skills	and	
teaching	patients	 to	generalize	 those	 skills	 to	 real-	world	naturalistic	
settings.52
5  | CONCLUSION
In	conclusion,	the	study	provides	evidence	supporting	the	association	
of	mood	 severity	 in	 acutely	 symptomatic	 BD	participants	with	me-
tabolites	of	the	KYN	pathway,	in	association	with	objective	measure-
ments	of	sleep.	Further	understanding	of	the	role	of	in	BD	is	important	
for	 the	 development	 of	 potential	 targets	 for	 intervention,	 or	mark-
ers	of	treatment	response.	Targeting	sleep	and	regulation	of	the	TRP	
breakdown	pathway	for	intervention	in	BD	participants	is	an	area	of	
research	warranting	 further	 investigation.	 Targeting	 these	 areas	 for	
improvement	and	observing	clinically	significant	changes	may	lead	to	
more	sustained	improvement	and	remission	rates.
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